OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) On A Bull Run

OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) is following the game plan we laid out for our subscribers back in November. We said that the stock was going to consolidate before heading higher. Shares have done just that and made new 52 week highs. OWCP is now up almost 8000% in the past year.What's most surprising is that even with the current gains, OWCP sports a market cap of just $33 million. When you consider that Medical Marijuana Inc (OTCMKTS:MJNA) has a $520 million market cap, Cannabis Sativa Inc (OTCMKTS:CBDS) a $119 million market cap, or Cannabis Science Inc (OTCMKTS:CBIS) a $157 million market cap, it's easy to make the case OWCP remains undervalued compared to its peers. Furthermore, there are a number of upcoming catalysts that we believe can keep OWCP on its upward trajectory.First up, a little background on the company. OWC Pharmaceutical Research Corp., through its wholly-owned Israeli subsidiary, One Word Cannabis Ltd., conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines. OWCP is also developing unique delivery systems for the effective delivery and dosage of medical cannabis.All OWCP research is conducted at leading Israeli hospitals and scientific institutions, and led by internationally renowned investigators. The Company’s Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids for the treatment of various medical conditions, while its Consulting Division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks.Israel is considered one of the best places in the world for cannabis research. According to The Cannabist, “Unlike the U.S. government, the Israeli government has had few restrictions on doing research on cannabis, whether basic science or clinical studies.” OWCP says that its research division “leverages the Company’s extensive network comprising some of Israel’s leading researchers, scientists, universities and hospitals, as well as cannabis breeders and extractors, to study and test the effectiveness of different combinations of cannabinoids in the treatment of disease and chronic conditions.”

To date, OWCP has signed three research collaboration and license agreements with Sheba Academic Medical Center, Tel Hashomer, Israel. Sheba is a university-affiliated hospital that serves as Israel’s national medical center and the most comprehensive medical center in the Middle East. Within the framework of the agreements with Sheba, OWCP will initiate three studies at the Sheba facilities to explore the effect of three formulations, all based on active ingredients in the cannabis extracts, on multiple myeloma, psoriasis and fibromyalgia (a specific formulation to each indication).

The Company has also signed a Memorandum of Understanding with Emilia Cosmetics Ltd., a large Israeli private label manufacturer, for the development, manufacture and marketing of a cannabinoid-based topical cream to treat psoriasis. The Company will initiate the development of the topical cream at Emilia Cosmetics labs located in Yerucham, Israel. After the completion of the formulation development, the Company will initiate a phase I study at the Sheba facilities to explore the effect of topical cream on psoriasis.In October, OWCP completed the development of a proprietary, cannabinoid-enriched sublingual tablet for the administration of medical cannabis. The technology behind the Tablet is protected and provides for the ingestion of virtually any dosage of medical cannabis with a sublingual delivery mechanism, whereby the compounds are absorbed directly into the patient’s blood through oral epithelial tissue. The Tablet also enables physicians to safely and accurately monitor the dosage and treatment of each individual patient, something that is essentially impossible to do for patients who administer cannabis by smoking.

OWCP is working towards having the Tablet approved by the Israeli Medicinal Cannabis Unit under the Ministry of Health office for use within the country’s sanctioned medical cannabis program, as well as talking with potential licensees of the technology in the United States. Longer term, management expects to establish clinical tests of the Tablet in protocols for Multiple Myeloma, Post-Traumatic Stress Disorder (PTSD), and Fibromyalgia.

Currently trading with a market cap of $33 million, there are presently 139 million shares outstanding and 86 million shares in the float. We are expecting news from the company any day now regarding its Tablet and/or its psoriasis topical cream. Either one will have the shorts scrambling and keep OWCP making new highs. In light of its low market cap compared to its peers, OWCP looks to be a must-own for cannabis investors. We will be updating our subscribers as soon as we know more. For the latest updates on OWCP, sign up below!

Disclosure: We have no position in OWCP and have not been compensated for this article.